Patents by Inventor Ronenn Roubenoff

Ronenn Roubenoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF LIVER DISEASE OR DISORDER COMPRISING ACTRII RECEPTOR ANTAGONISTS
    Publication number: 20220340668
    Abstract: The present disclosure provides an ActRII antagonist, e.g., the ActRIIA and/or ActRIIB antagonist, e.g., an anti-ActRII receptor antibody or antigen-binding fragment thereof, e.g., bimagrumab, for treating or preventing liver disease or disorder in a subject in need thereof. The present disclosure also relates to pharmaceutical combinations comprising such ActRII antagonists and at least one further therapeutic agent in the treatment or prevention of liver disease or disorder.
    Type: Application
    Filed: September 1, 2020
    Publication date: October 27, 2022
    Inventors: Laura COLEMAN, C. Daniel MEYERS, Ronenn ROUBENOFF, Estelle TRIFILIEFF
  • USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF
    Publication number: 20220265823
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Shinji HATAKEYAMA, Ronenn ROUBENOFF, Estelle TRIFILIEFF, Jerome FEIGE, Lloyd B. KLICKSTEIN
  • Uses of myostatin antagonists, combinations containing them and uses thereof
    Patent number: 11357851
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilieff, Jerome Feige, Lloyd B. Klickstein
  • MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONS
    Publication number: 20210363263
    Abstract: The present invention relates to myostatin or activin antagonists or receptor antagonists for use in improving body composition, e.g., for the treatment of central adiposity, obesity or overweight condition and related comorbidities. The present invention also relates to myostatin or activin antagonists or receptor antagonists for the treatment of type II diabetes by improving glycemic control, in particular by increasing insulin sensitivity.
    Type: Application
    Filed: March 2, 2021
    Publication date: November 25, 2021
    Inventors: Tania Silvia GARITO, Ronenn ROUBENOFF, Marjorie ZAKARIA
  • USES OF MYOSTATIN ANTAGONISTS, COMBINATIONS CONTAINING THEM AND USES THEREOF
    Publication number: 20200254090
    Abstract: The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment. In particular, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.
    Type: Application
    Filed: November 9, 2016
    Publication date: August 13, 2020
    Inventors: Shinji Hatakeyama, Ronenn Roubenoff, Estelle Trifilirff, Jerome Feige, Lloyd B Klickstein
  • MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONS
    Publication number: 20190345251
    Abstract: The present invention relates to myostatin or activin antagonists or receptor antagonists for use in improving body composition, e.g., for the treatment of central adiposity, obesity or overweight condition and related comorbidities. The present invention also relates to myostatin or activin antagonists or receptor antagonists for the treatment of type II diabetes by improving glycemic control, in particular by increasing insulin sensitivity.
    Type: Application
    Filed: December 20, 2017
    Publication date: November 14, 2019
    Inventors: Tania Silvia Garito, Ronenn ROUBENOFF, Marjorie ZAKARIA
  • Methods of treating Sporadic Inclusion Body Myositis
    Publication number: 20180066061
    Abstract: The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: September 28, 2017
    Publication date: March 8, 2018
    Inventors: Dimitris Papanicolaou, Ronenn Roubenoff, Brian Tseng, Charles Gubser, David Glass
  • MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA
    Publication number: 20170260275
    Abstract: The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.
    Type: Application
    Filed: December 4, 2015
    Publication date: September 14, 2017
    Inventors: Patrick KORTEBEIN, Daniel ROOKS, Lloyd B. KLICKSTEIN, Ronenn ROUBENOFF, David GLASS, Estelle TRIFILIEFF, Dimitris PAPANICOLAOU
  • BIOMARKERS PREDICTIVE OF MUSCLE ATROPHY, METHOD AND USE
    Publication number: 20170248609
    Abstract: This invention is in the field of Biomarkers. In particular, it relates to biomarker being predictive of muscle atrophy. The invention relates to the use of such biomarker for selectively treating a patient having muscle atrophy and a method of predicting the likelihood that a patient having muscle atrophy will respond to treatment with a muscle anabolic agent.
    Type: Application
    Filed: January 26, 2015
    Publication date: August 31, 2017
    Applicant: Novartis AG
    Inventors: Stefan REINKER, Ronenn ROUBENOFF, Yingqi Karen WANG, Kan ZHU
  • Methods of treating Sporadic Inclusion Body Myositis
    Publication number: 20160200818
    Abstract: The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an ActRII receptor binding molecule, an ActRII receptor antibody, such as the bimagrumab antibody.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 14, 2016
    Applicant: Novartis AG
    Inventors: Dimitris PAPANICOLAOU, Ronenn ROUBENOFF, Brian TSENG, Charles GUBSER, David GLASS
  • Compositions and methods for treating an arthritic condition
    Publication number: 20050113332
    Abstract: The present invention features compositions and methods for the treatment of an arthritic condition. The compositions contain a reduced folate compound and a cobalamin compound.
    Type: Application
    Filed: November 2, 2004
    Publication date: May 26, 2005
    Inventors: Ronenn Roubenoff, Jacob Selhub
  • Compositions and methods for treating an arthritic condition
    Publication number: 20020094970
    Abstract: The present invention features compositions and methods for the treatment of an arthritic condition. The compositions contain a reduced folate compound and a cobalamin compound.
    Type: Application
    Filed: December 14, 2001
    Publication date: July 18, 2002
    Inventors: Ronenn Roubenoff, Jacob Selhub